Clinical Trials for Women's Cancers

Clinical Trials for Women’s Cancers

Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of on-going research.

The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.

Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.

Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.

The following clinical trials are open to enrollment.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.
Type of CancerProtocol ID & Study Title
Cervical or Pre-CancerCerGE
Women who have been treated for cervical cancer may be eligible for a current study on genetic susceptibility to that cancer. Exposure to the human papillomavirus (HPV) can lead to cervical cancer, but it doesn’t always.
A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis Immunotherapy to prevent Cervical recurrence)

Keywords: Cervical, ADXS11-001, Adjuvant, High risk, Locally Advanced, AIM2CERV, Phase 3
CervicalADVAXIS ADXS 001-04
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer

Keywords: Cervical, Recurrent, Metastatic, ADXS11-001, Randomized
CervicalGOG 263
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Keywords: Stage I/IIA Cervical Cancer
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Keywords: Randomized, Phase II, Cisplatin, Stage II-IVA
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Keywords: Endometrial, GOG-0286B, Phase II/III, Recurrent, Stage III, Stage IVA, Stage IVB
EndometrialT Regulatory Cells and DNA Methylation in Early Endometrial Cancer Before and After Treatment

Keywords: Endometrial
EndometrialTesaro TSR-042 4010-01-001
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD1 Monoclonal Antibody in Patients with Advance Solid tumors

Keywords: Endometrial, Tesaro, TSR-042, Advanced, 4010-01-001, Phase 1, Anti-PD1 Monoclonal Antibody, Solid Tumors
N/A Pre-cancer, HPVINOVIO- HPV-201
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva

Keywords: Pre-Cancer, Vulvar, VIN, HPV
OvarianGOG 225
Can Diet and Exercise Modulate Ovarian, Fallopian Tube or Peritoneal Cancer Progression-Free Survival?

Keywords: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Change, Healthy Lifestyle
OvarianGOG 3011/Immunogen
Forward 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α–positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer Or Fallopian Tube Cancer

Keywords: Forward 1, Phase 3, Mirvetuximab Soravtansine, IMGN853, Immunogen, Folate receptor α-positive, Epithelial, Ovarian, Primary Peritoneal, Fallopian tube
OvarianGOG 3012 - TESARO
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Keywords: HRD-positive, advanced Ovarian, Niraparib, Randomized, Double-blind
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Keywords: Phase III, Olaparib, Cediranib, Platinum-Based, Ovarian
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Keywords: Randomized, Cediranib, Olaparib, Ovarian, Platinum Resistant
A Phase I/II STUDY OF Ruxolitinib With Front-Line Neoadjuvant And Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Keywords: Ruxolitinib, Neoadjuvant, Epithelial Ovarian
OvarianIIT-Uyar Merck 3475-250
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Keywords: Suboptimal Cytoreduced, Ovarian, Pembrolizumab, First Line, Epithelial, Nonrandomized
OvarianJanssen R&D Protocol ET743-OVC-3006
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Keywords: Randomized, Open Label, Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Relapsed, Phase 3, Recurrent Ovarian Cancer, Doxil, Yondelis, BRCA, Platinum Sensitive, Third Line

Learn More

fmlh-mcw-boxLearn more about the Gynecologic Cancer Program on the Froedtert & the Medical College of Wisconsin website.